Lecture 6: Antiarrhythmic Classification & MOA Flashcards

1
Q

LO: Antiarrhythmic Classification: Vaughan-Williams

A

1.) Class 1: Sodium Channel blockers
2.) Class 2: Beta Blockers
3.) Class 3: Potassium Channel Blockers
4.) Class 4: Calcium Channel Blockers
5.) Other: Adenosine, digitalis, atropine, magnesium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

LO: Know which antiarrhythmic drug works in which myocardial tissue

A

NOTE: so when you are looking for drugs to treat a specific area you will know which drugs act where.. Atropine is use for slow arrythmia to increase conduction!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

LO: Describe the different MOA for antiarrhythmic agents.

A

1.) Slow conduction velocity of AP
– Increase refractoriness (changes in effective refractory period and action potential duration)
– Create a two way block in reentry circuit
.
2.) Change the slope of Phase 4
– Decrease (e.g. beta blockers) or increase automaticity (e.g. atropine, epinephrine)
.
3.) Change the threshold potential or maximum diastolic potential
– Decrease or increase automaticity (further away from threshold = decrease automaticity/ heart rate!)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

LO: Class IA MOA and how it works . . .

A

Class IA decrease the slope of phase 0/ slow phase 0 depolarization, which prolong action potential and slow down the conduction . Will have direct effect on the myocytes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Drug affecting the cardiac action potential/ which part of action potential it is affecting

A

Class 1 agent: Na channel blocker affects phase 0, class 4 agents will affect phase 0 in SA and AV node. Class 3 agents will effect repolarization of phase 3 . class 2 agents (beta blocker) will really effect the slope of phase 4!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Drug affecting the cardiac action potential/ which part of action potential it is affecting (looking at the effects on the slope of action potential)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

LO: Know which drugs effect QT and PR intervals and the overall effect on the ECG

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

LO: Know which drug classes increase refractoriness in myocardial tissue
Know which drugs affect AV nodal conduction (decrease or increase)

A

NOTE: all drug treat fast arrythmias except for atropine (slow only)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

LO: Proarrhythmia (Torsades De Pointes): What is it? (general) List risk factors for developing proarrhythmic event… List the antiarrhythmic drugs that are the highest risk for proarrhythmic events!

A
  • Rapid form of polymorphic ventricular tachycardia
  • Often preceded by a prolonged QT interval (so that’s why we monitor drugs that prolong QT!)
  • Often in patients with structural heart disease
  • Often caused by drugs; other conditions (hypokalemia, hypomagnesemia, congenital QT syndrome, etc) may also contribute
    .
    RISKS
  • AA drugs that prolong QT intervals may induce arrhythmias
  • This is way we monitor the QTc interval. A prolonged QTc interval puts patients at risk for proarrhythmic event.
  • Highest Risk for Proarrhythmic Events: Class IA agents, Class IC agents, ibutilide, dofetilide, sotalol.
  • Lower Risk for Proarrhythmic Events: Amiodarone, lidocaine, mexiletine, Class II. (important to know! lets say you have a patient at higher risk for arrythmia - eg. patient who has structural heart disease! you want to have them on the lower risk drugs: 1st Amiodarone)
  • Highest Risk Factors: Structural heart disease (low EF), CAD, baseline prolonged QTc (drug induced or congential), electrolyte disturbances (hypokalemia)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

LO: Proarrhythmia (Torsades De Pointes): Know how to treat torsades de pointes

A
  • If severely symptomatic – electrocardioversion (cardioversion, defibrillation)
  • Magnesium - suppresses early afterdepolarizations (EADs) and
    helps terminate the arrhythmia. Magnesium achieves this by
    decreasing the influx of calcium, thus lowering the amplitude
    of EADs.
  • Correct electrolyte imbalances if presented, remove offending
    drug if presented.
  • Isoproterenol - accelerates AV conduction and decreases the QT interval by increasing the heart rate and reducing temporal dispersion of repolarization
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Drugs associated with the development of proarrhythmia (hint: some of them are not AA!) (not LO)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What Drugs for What Arrhythmias and Effects on ECG?
1. Sinus arrhythmias
2. Sinus Bradycardia
3. Atrial fibrillation
4. AV-Node reentry tachycardia
5. AV-Block
6. Ventricular Tachycardia

A
  1. Sinus (SA) arrhythmias - beta blocker, CCB, (what about nifedipine? NO- dihy CCB wont work on SA node?) decrease HR and increase PR
    .
  2. Sinus Bradycardia - atropine
    .
  3. Atrial fibrillation - Class 3, quinidine, class IB, Class IC, (class 2 wont work! Beta Blockers cuz it only works in SA AV node), Class 3, digoxin (class 5)? NO! wont work!
    .
  4. AV-Node reentry tachycardia - IC, IB? no need to monitor, Class IA and IC? need to monitor QT ! Class 3: need to monitor QT
  5. AV-Block
  6. Ventricular Tachycardia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MORE MOVING ON TO ATRIAL FIB

A

YES

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

LO: Define AF and ventricular response rate (VRR) and the importance of AV node

A

Atrial fibrillation (AF) is a supraventricular (above the ventricles) tachyarrhythmia characterized by
- Uncoordinated atrial activation → deterioration of mechanical function
- A. Fib characterized by chaotic atrial activity (atrial rate *500-600 beats per minute)
- A. flutter characterized by fast regular atrial activity ( ~ 300 beats per minute)
- AV node allows some of the atrial impulses to depolarize the ventricles; ventricular (QRS) rate is irregular pattern (for a. fib) and sometimes a regular pattern (for a. flutter, e.g. 2:l block).
.
NOTE:
In a normal sinus rhythm- youi have P-QRS-T waves! SA node fire and atrium will contrast and come to the AV node where it will slightly delay and then it will go down his punjikie system where it travels down towards bottom on the heart where it will excite and travel and causes contractility. In an A fib heart, what we see is maybe the area of the heart just throwing out a ton of impulses. The atrium can be contracting by itself without the signal from SA node! Contracting sooo fast! 500-600 BPM! SA node still firing but atrium doesn’t care..its firing independently. Atrium is going v fast, but ventricle is only going 150 BPM..why? what’s blocking it? thank goodness we still have the AV node to block that signal! The AV node is getting bombarded with signals/ impulses but it cannot handle all of them so it only lets like 150-160 BPM IF it was not for the AV node ventricles or if there was a bypass, it would go 600BMP = ventricular fibrillation! What are two areas you wanna hit to treat afib? atrium and AV node (slow conduction). You can also easily diagnosis a fib look at ECG! When comparing AFib to AFlutter- AFlutter is a bit more stable and ECG looks more consistent and it is only going 300BPM (1 sharp - 3 tiny hump- 1 sharp)
.
Importance of AV NODE:
Without the AV-node all the impulses from the atrium (300- 600 bpm) would be conducted to the ventricle’s leading to ventricular rates of 300-600 bpm – this is not compatible with life (ventricular fibrillation!)
- Because the AV-node is there, not all atrial impulses are transmitted, usually only 120-150 impulses can get through per minute. Therefore, the ventricles are beating at a rate of 120-150 bpm (VENTRICULAR RESPONSE RATE - VRR) which most patients can tolerate, patients can generate enough cardiac output (although they may be symptomatic).
- A goal of rate control therapy in atrial fibrillation/flutter is to
decrease VRR to between 80 to 110 bpm.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Epidemiology – Why Afib is Important

A
  • More than 200,000 cases per year.
  • Incidence increased 13% over past 20 years
  • In USA, 12-16 million will be affected by 2050
  • Increasing obesity and increasing age are risk factors that help explain rise in incidence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

LO: Define the pathophysiology and risk factors for AF.

A

PATHO:
-Atrial Structure Abnormalities -changes of electrical conduction
——-#1 risk: Atrial dilation (increase pressure – e.g. heart failure)
——-Fibrosis
——-Ischemia
-Inflammation, Oxidative Stress
-Hyperthyroidism (get thyroid level for all patients with Afib
-Alcohol and drug use
-Genetic Variants
.
RISK FACTORS
-Hypertension
-Heart Disease – especially Heart Failure
-Hyperthyroidism
-Excessive to moderate alcohol
-Obesity
-Sleep Apnea
-High Dose Fish Oil (> 1 gm - usually around 4 grams)
-Non modifiable - AGE

17
Q

LO: List the symptoms associated with AFib

A

EXCEPT for palpitation, all of these symptoms are due to decrease CO due to decrease SV! you don’t have time to fill vesicle and push blood out cuz heart is beating so fast! so that’s why you have lower CO. You also loss your atrial kick! so makes symp worse…Futhermore …PATIENTS CAN BE ASYMPTOMATIC! THIS IS AN ISSUE!

18
Q

LO: List outcomes associated with AF: Atrial Fibrillation / Flutter Is Associated with Increased Morbidity and Mortality

A
  • Thromboembolism / stroke: 5-fold increase in risk
  • Death: 2-fold increase in risk
  • Tachycardia-induced worsening of associated myocardial ischemia or heart failure
  • Cardiovascular hospitalization: 2 to 3-fold increase in risk
  • Risk increase in both Symptomatic or asymptomatic patient! if you do not know you have it? you’re a ticking time bomb!
19
Q

Definitions of AF: A Simplified Scheme

A
20
Q

LO: What is Rate Control? What is Rhythm Control?

A
  1. Rate Control – slowing down the number of impulses going from the atrium to the ventricle when the patient is in atrial fibrillation (Slow or block the number of impulse going through the AV node with AV node blocking drugs or by destroying the AV node).
    NOTE: is where the person stay in afib but we reduce how fast ventricular contrast (ventricular response rate)
    .
    2.) Rhythm Control – Converting the atrial fibrillation (the arrhythmia in the atrium) back to normal (AA therapy or electrocardioversion) resulting in the patient being back in normal sinus rhythm. Once the patient is back in normal sinus rhythm antiarrhythmic therapy (or ablation therapy) may be used to maintain sinus rhythm
    NOTE: bringing this person back to normal rhythm sinus rate
21
Q

Rate Control (alone) or Rate Control + Rhythm Control

A
22
Q

LO: Rhythm vs Rate Control

A

General Rhythm vs Rate Control:
-Rate control may be the only option in some patients in which normal sinus rhythm cannot be maintained (permanent AF) or due to adverse drug effects or risk (from AA drug/ cannot use AA drug so cannot do rhythm control).
-Rhythm control is preferred in patients with symptoms despite rate control, including those with persistent symptoms of heart failure.
- Outcomes appear to be similar between rhythm vs rate control.
.
Rate Control
- Decrease the ventricular response rate (how fast the ventricles are contracting)
- A ventricular response rate control strategy (resting heart
rate <80 bpm) is reasonable for symptomatic management of AF.
- A lenient rate-control strategy (resting heart rate <110 bpm)
may be reasonable as long as patients remain asymptomatic and LV systolic function is preserved.
-Use drugs that decrease AV node conduction
.
Rhythm Control
- Monitor: Afib Burden – how often do patients go back into atrial fibrillation
- Need to monitor for adverse effects and drug interactions for the antiarrhythmic agent selected.
——- For example, if patient is on warfarin and amiodarone is started need to evaluate for significant drug interaction.
——- QTc monitoring
- Of Note: Rhythm control requires more monitoring and patients are at greater risk for adverse effects than patients on rate control

23
Q

Atrial Fibrillation Decision Tree: what to do with the patient

A

Step 1: hemodynamic unstable? BP 70/nothing, passing out? shock them! Electricity!!!..not very common… most are stable! if they are stable? 2 things we need to start right away –> IV hep or LMWH and slow down ventricular response rate (IV - beta blocker or IV diltizem eg.)
Then step 3 (assess duration of arrhythmia!) Less than 48hrs? less likely there is no clot so just do cardioversion. if it is more than 48 hr’s or unknown time there are changes of clots! so you need to do anticoag!
.
HOWEVER - if a patient is already on anticoagulation when they come in? no need to give IV hep/ LMWH cuz they are already anticoag. We need to do rate control agent!

24
Q

Transesphageal Echocardiogram (TEE)

A

This type of Echo versus a surface echo can tell if
there is a clot in the heart. If no clot is visible can
immediately cardiovert (shock) back to normal sinus rhythm.
.
If there is a clot? need anticoag!

25
Q

Common drug use for rate control..notice which is IV (need to give IV inpatient) then they can switch to PO

A

know general table

26
Q

LO: CHRONIC Rate Control for other co morbidity

A
27
Q

LO: Rate Control – General Monitoring

A
  • Ventricular response rate – measure pulse or ECG or smart device or telemetry
  • A ventricular response rate control strategy (resting heart rate <80 bpm… 110 is acceptable)) is reasonable for symptomatic management of AF.
  • A lenient rate-control strategy (resting heart rate <110 bpm) may be reasonable as long as patients remain asymptomatic and LV systolic function is preserved.
  • Blood pressure – most rate control drugs can decrease blood pressure
  • Calcium channel blockers can cause constipation and heartburn.
  • Beta blockers can lead to fatigue and decrease exercise
    tolerance.
28
Q

LO: Rate Control – General Monitoring- Digoxin

A
  • Monitor serum levels (levels < 1ng/mL is best, but may need to go higher and probably not > 1.5 ng/mL). Trough concentrations, remember long t1/2 (~ 48 hrs +)
  • Monitor bradycardia
  • Nausea and vomiting, halo vision
  • Caution in renal dysfunction (renally excreted)
  • Hypokalemia increase toxicity
  • Toxicity can lead to fatal brady or tachy arrhythmias.
  • Review your HF notes!
28
Q

LO: Rate Control – General Monitoring- Digoxin

A
  • Monitor serum levels (levels < 1ng/mL is best, but may need to go higher and probably not > 1.5 ng/mL). Trough concentrations, remember long t1/2 (~ 48 hrs +)
  • Monitor bradycardia
  • Nausea and vomiting, halo vision
  • Caution in renal dysfunction (renally excreted)
  • Hypokalemia increase toxicity
  • Toxicity can lead to fatal brady or tachy arrhythmias.
  • Review your HF notes!
29
Q

Rhythm Control - how do we do it?

A

Cardioversion to normal sinus rhythm from Afib.
-Electrical
-Pharmacological
-Patient on their own converts (paroxysmal) – so not all patients will need to be cardioverted by electrical or pharmacological means
.
Maintenance of normal sinus rhythm if needed (prevent Afib from coming back)
-Pharmacological
-Ablation

30
Q

Rhythm Control – General Monitoring

A
  • Afib Burden – how often do patients go back into atrial fibrillation
  • Need to monitor for adverse effects and drug interactions for the antiarrhythmic agent selected.
    ———For example, if patient is on warfarin and amiodarone is started need to evaluate for significant drug interaction.
    ——–QTc monitoring
31
Q

Strategies for Rhythm Control in Patients with Paroxysmal and persistent AF (VW CLASS IC, III)

A
32
Q

Rhythm Control
Pill-in-the-Pocket

A
  • Some patients with recurrent atrial fibrillation may present with episodes that are not frequent and are well tolerated but that are long enough in duration that they require either emergency room intervention or hospitalization.
  • Oral prophylaxis or catheter ablation may not be the most appropriate
    first-line treatment for such patients.
  • An alternative treatment is the “pill-in-the pocket” approach, in which the patient self-administers a single oral dose of an antiarrhythmic drug at the time of the onset of palpitations. The class IC agents flecainide and propafenone have the advantage of acting rapidly and is effective and should be combined with a beta-blocker or non-dihydropyridine CCB.
33
Q

Which of the following is most effective in decreasing ventricular response rate?
a. amiodarone
b. beta blockers
c. digoxin
d. AV-nodal ablation
e. diltiazem

A

all of these to some degree is effective…but the most effective one is
.
Beta blocker acts on the ventricle yes.. but thru indirect mech? so BB?

34
Q

Which of the following will convert patients from AF to NSR?
a. amiodarone
b. metoprolol
c. digoxin
d. diltiazem
e. all the above

A

A! b/c it works in atrium! :) but the other ones works in the Av and SA node! NOT Atrium!

35
Q

1.) Why does this patient have DOE and palpitations?
2.) What are patient risk factors for atrial fibrillation
3.) What additional labs do you want to draw if any?
4.) What is the greatest morbidity risk to this patient?
5.) What are your acute therapeutic recommendations for the patient?
6.) What is your therapeutic recommendation upon discharge?

A

1.) Why does this patient have DOE and palpitations? He’s in AFIB
2.) What are patient risk factors for atrial fibrillation: Age, HTN, obesity, alcohol use, hyperthyroidism
3.) What additional labs do you want to draw if any?: Thyroid!
4.) What is the greatest morbidity risk to this patient?: Afib-> STOKE!
5.) What are your acute therapeutic recommendations for the patient? rate control and anticoagulation-> IV heparin or LMWH, IV diltiazem (for rate control)…what about IV Beta Blocker? yes! We can! :)
6.) What is your therapeutic recommendation upon discharge?

36
Q

When to Caridovert and use Chronic Therapy for Prevention or Just Rate Control?

A
  • First or isolated Episodes – usually convert and then send home (+/- rate
    control but no antiarrhythmic therapy) and see what happens.
  • Second/Third (recurrent) episodes need to make a decision whether to try to prevent further episodes with antiarrhythmic drugs or keep in AF and just rate control. Outcomes are similar for either option. Either approach is appropriate at this point, patient specific.
  • Patient symptomatic in AF despite good rate control – need to cardiovert
    and use antiarrhythmic agents to prevent future episodes. If drugs cannot
    prevent recurrence of AF, ablation of areas where AF may be occurring
    using radiofrequency or other methods may be tried.